title: Utilization of adjuvant therapies and their impact on survival for women with stage IIIC endometrial adenocarcinoma.
abstract: Adjuvant treatment options following surgical staging for women with stage IIIC endometrial carcinoma include chemotherapy (CT) with or without radiation therapy (RT). We utilized the National Cancer Database (NCDB) to investigate utilization of adjuvant CT and RT for this group of patients and assess their impact on overall survival (OS).
  
  
  
  The NCDB was queried for patients diagnosed with non-metastatic surgically staged uterine adenocarcinoma between 2004 and 2011 with at least one pathologically positive lymph node. Overall survival (OS) was analyzed using the Kaplan-Meier method. Comparison was made between patients receiving no additional therapy, RT alone, CT alone, or a combination of CT and RT (CMT). Multivariable cox regression analysis (MVA) was performed to evaluate the effect of covariates on OS.
  
  
  
  A total of 6720 patients were included in this study. Of whom, 1409 received no adjuvant treatment, 1533 received CT only, 1265 received RT only, and 2522 received CMT. The 5-year OS for patients receiving no adjuvant therapy, RT alone, CT alone, and CMT were 54.9%, 63.9%, 64.4%, and 72.6%, respectively. On pairwise analysis, CMT was associated with improved survival compared to all other subgroups (p<0.001). On MVA, CMT (HR 0.58, 95% CI 0.52-0.66, p<0.001) was the strongest predictor for improved OS compared to RT alone (HR 0.79, 95% CI 0.69-0.89, p<0.001) or CT alone (HR 0.75, 95% CI 0.66-0.85, p<0.001).
  
  
  
  Both adjuvant CT and adjuvant RT were associated with improved OS for women with stage IIIC endometrial adenocarcinoma, but CMT was associated with the largest improvement in OS.
authors.affiliation: Department of Veterans Affairs, New York Harbor Healthcare, Brooklyn, NY, USA; SUNY Downstate Medical Center, Brooklyn, NY, USA. Electronic address: andrew.wong@downstate.edu.
authors.forename: Andrew T
authors.initials: AT
authors.lastname: Wong
authors.affiliation: UF Health Cancer Center - Orlando Health, Orlando, FL, USA.
authors.forename: Justin
authors.initials: J
authors.lastname: Rineer
authors.affiliation: SUNY Downstate Medical Center, Brooklyn, NY, USA.
authors.forename: Yi-Chun
authors.initials: YC
authors.lastname: Lee
authors.affiliation: Department of Veterans Affairs, New York Harbor Healthcare, Brooklyn, NY, USA; SUNY Downstate Medical Center, Brooklyn, NY, USA.
authors.forename: David
authors.initials: D
authors.lastname: Schwartz
authors.affiliation: Department of Veterans Affairs, New York Harbor Healthcare, Brooklyn, NY, USA; SUNY Downstate Medical Center, Brooklyn, NY, USA.
authors.forename: Joseph
authors.initials: J
authors.lastname: Safdieh
authors.affiliation: Department of Veterans Affairs, New York Harbor Healthcare, Brooklyn, NY, USA; SUNY Downstate Medical Center, Brooklyn, NY, USA.
authors.forename: Joseph
authors.initials: J
authors.lastname: Weiner
authors.affiliation: SUNY Downstate Medical Center, Brooklyn, NY, USA.
authors.forename: Kwang
authors.initials: K
authors.lastname: Choi
authors.affiliation: Department of Veterans Affairs, New York Harbor Healthcare, Brooklyn, NY, USA; SUNY Downstate Medical Center, Brooklyn, NY, USA.
authors.forename: David
authors.initials: D
authors.lastname: Schreiber
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D000368:Aged; D059186:Chemoradiotherapy, Adjuvant / Q000706:statistics & numerical data; D017024:Chemotherapy, Adjuvant / Q000706:statistics & numerical data; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D018714:Radiotherapy, Adjuvant / Q000706:statistics & numerical data; D012042:Registries; D014481:United States / Q000453:epidemiology
keywords: Chemotherapy; Combined modality therapy; Endometrial adenocarcinoma; Radiation therapy; Uterine adenocarcinoma